Clinical Trials Logo
  1. Home
  2. Lobular Breast Carcinoma
  3. NCT05931302

Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT — GALILEE  

Lobular Breast Carcinoma Clinical Trial

Official title:
Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT

Clinical Trial Summary

Lobular Breast cancer staging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is not optimal due to the poor accumulation of 18F-FDG in the tumour. Through better sensitivity (and specificity), 68Ga-FAPI-46-46 PET should provide a more accurate staging of lobular breast cancer than 18F-FDG PET.

Clinical Trial Description

Research hypothesis : Through better sensitivity (and specificity), 68Ga-FAPI-46-46 PET should provide a more accurate staging of lobular breast cancer than 18F-FDG PET. Participants with lobular breast carcinoma will then undergo 18F-FDG and 68Ga-FAPI-46 PET scan. Primary objective of the study is to compare the sensitivity of 68Ga-FAPI-46 with the sensitivity of 18F-FDG in the detection of lobular breast carcinoma lesions, measured by positron emission tomography (PET). These results will be compared with the histological data collected before or during surgery (conventional histological data and immunohistochemical labeling of FAPĪ± on the sample obtained), clinical follow-up and any results of additional examinations carried out within the usual clinical follow-up of the patients. Comparison of primary tumor and metastases uptake of 68Ga-FAPI-46 with the uptake of 18F-FDG, radiomic study of 68Ga-FAPI-46 PET and comparative radiomic study of 68Ga-FAPI-46 PET and 18F-FDG PET and comparison of the specificity of 68Ga-FAPI-46 with the specificity of 18F-FDG after a 12-month follow-up will also be performed as secondary objectives. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05931302
Study type Interventional
Source Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Contact Florent Hugonnet, MD
Phone 07 97 98 96 59
Email florent.hugonnet@chpg.mc
Status Recruiting
Phase N/A
Start date November 16, 2023
Completion date April 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05982496 - 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer N/A
Active, not recruiting NCT03620643 - Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours Phase 2
Completed NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer Early Phase 1
Recruiting NCT06067503 - Biomarkers to Detect Endocrine Therapy Resistance Phase 2
Recruiting NCT05410951 - LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
Active, not recruiting NCT03414970 - Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer Phase 3
Recruiting NCT05837767 - A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue N/A
Active, not recruiting NCT01038258 - Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy N/A
Completed NCT03834532 - Living Well After Breast Surgery N/A
Recruiting NCT05964504 - Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Active, not recruiting NCT04206891 - CDH1 Germline Mutations in Lobular Breast Cancer